SOLUBILITY ENHANCEMENT OF A MODEL ETORICOXIB DRUG USING LIQUISOLID COMPACTS
The objective of the present study was to improve Etoricoxib dissolution through formulation into Liquisolid Compacts (LSC) and to investigate their in vitro performance. By using LSC technique liquid medications such as solutions and suspensions of water insoluble drugs in suitable non-volatile liquid vehicles can easily be converted into powder with acceptable flow properties and compression behavior by using appropriate powder excipients. FTIR, DSC, XRD and SEM studies were used for evaluation of physic-chemical properties of Etoricoxib in LSC tablets. SEM was used to assess morphological character of LSC formulation. Enhancement in the drug solubility as compared to the pure drug is due to increased wetting properties and surface of the drug available for dissolution. All the tested liquisolid tablet formulations showed higher drug dissolution rates (DR) than directly compressed tablets. In addition, the selected optimal formula (LS 12) released 69.20% of its content during the first 10 min which is 44% higher than that of the directly compressed tablets. The present study results concluded that Liquisolid Compact technique enhances the dissolution rate and the bioavailability of Etoricoxib.